Trials / Completed
CompletedNCT00621647
Seroquel- Agitation Associated With Dementia
A Multicenter, Double-Blind, Randomized, Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated With Dementia.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 333 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine how safe and effective Seroquel (quetiapine fumarate) is compared to placebo (a non-drug tablet) for a period of up to 10 weeks in the treatment of agitation symptoms in nursing home or assisted care residents. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Quetiapine Fumarate | |
| DRUG | Quetiapine Fumarate | |
| DRUG | Placebo |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2003-11-01
- Completion
- 2003-11-01
- First posted
- 2008-02-22
- Last updated
- 2009-03-25
Source: ClinicalTrials.gov record NCT00621647. Inclusion in this directory is not an endorsement.